Clinical trials: Allergy; Dermatitis
Atopic Dermatitis
Treatment of AD With IgE Specific Immunoadsorption (IGEIAAD)
Removal of IgE through adsorption of IgE on a specially designed column after apheresis of blood has the potential to improve the severity of atopic dermatitis.
- Trial name
- IGEIAAD (NCT02365246)
- Testing
- immunoadsorptions with an IgE-specific adsorption column
- Where
- Belgium
- Volunteers
- 15 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Atopic Dermatitis
An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic (PK) parameters of the combination of APG777 + APG990 in adults with moderate-to-severe atopic dermatitis (AD), in comparison to…
- Trial name
- NCT07027527
- Testing
- APG777, APG990, Dupilumab
- Where
- 20 sites in Australia, Canada and 1 more
- Volunteers
- 86 people
- Sponsor
- Apogee Therapeutics, Inc.
Atopic Dermatitis
Dynamic Blood Inflammatory Profile in Atopic Dermatitis Patients (ADAMUNE)
This is a prospective, single-center, class 2 study to better characterize the immune response in immune response in the blood of atopic dermatitis.
- Trial name
- NCT05868824
- Testing
- Blood sample
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Food Allergy, Eczema
Treatment of IgE Associated Eczema With Omega-3 Long Chain Polyunsaturated Fatty Acids in Infancy and the Development of Bronchial Asthma in Childhood
Although some causal factors in allergy development such as allergen exposure and environmental pollution have decreased during recent years, the incidence of the allergic diseases has increased in the Western world.
- Conditions
- Food Allergy, Eczema, Sensitisation
- Trial name
- Omega-Treat (NCT01473823)
- Testing
- Omega-3 LCPUFA
- Where
- Sweden
- Volunteers
- 160 people
- Sponsor
- Ostergotland County Council, Sweden
Dermatitis, Atopic
Intervention Study to Evaluate a Probiotic in Mild Atopic Dermatitis Young Patients
The aim of the study is to evaluate the beneficial effect of a probiotic preparation with an antiinflammatory and modulating activity on immunological processes, with positive results on different inflammatory and atopic…
- Trial name
- NCT02585986
- Testing
- Probiotic
- Where
- Spain
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Biopolis S.L.
Atopy, Asthma
Vitamin A Supplementation at Birth and Atopy in Childhood
INTRODUCTION Eight trials studying the effect of providing neonatal vitamin A supplementation (NVAS) have been reported, and another four are underway to test whether NVAS should become WHO policy.
- Conditions
- Atopy, Asthma, Eczema, Food Allergy
- Trial name
- NCT01779180
- Where
- Guinea-Bissau
- Volunteers
- 2,000 people
- Sponsor
- Bandim Health Project
Hemay005, Atopic Dermatitis
A Study of Hemay005 in Adult With Atopic Dermatitis
A multicenter, randomized, double-blind, placebo-controlled, phase II study to evaluate the efficacy and safety of Hemay005 tablet in the treatment of moderate to severe atopic dermatitis.
- Trial name
- NCT05769946
- Testing
- Hemay005
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
Atopic Dermatitis
A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.
To demonstrate the therapeutic equivalence and safety of Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) and OPZELURA (Ruxolitinib) Cream in the treatment of mild-to-moderate atopic dermatitis
- Trial name
- NCT06673654
- Testing
- Ruxolitinib Topical Cream 1.5%, OPZELURA (Ruxolitinib) Cream
- Where
- United States
- Volunteers
- 476 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Atopic Dermatitis, Hidradenitis Suppurativa (HS)
A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients
The goal of this clinical trial is to evaluate the safety, tolerability, PK, and PD of single and multiple ascending doses of QLS12010 Capsules and the effect of food on their PK profiles in healthy adult participants and…
- Conditions
- Atopic Dermatitis, Hidradenitis Suppurativa (HS), Rheumatoid Arthritis (RA)
- Trial name
- NCT06946641
- Testing
- QLS12010
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTD
Atopic Dermatitis
Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis
A Phase I/IIa Randomized, Double-Blind, Vehicle-Controlled Clinical Trial with Separate Open-Label Active Treatment Phase Evaluating the Safety, Pharmacokinetics and Efficacy of FMX114 Gel in the Treatment of Mild-to-Moderate…
- Trial name
- NCT04927572
- Testing
- FMX114, Vehicle
- Where
- 7 sites in United States, Australia
- Volunteers
- 21 people
- Sponsor
- Vyne Therapeutics Inc.
Dermatitis, Atopic
Investigation of Topical SB705498 on Healthy Volunteers
A two part, randomized, double-blind, placebo controlled study to investigate the effects of topical doses of SB705498 in healthy volunteers.
- Trial name
- NCT01673529
- Testing
- SB705498
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
Evaluating the Effects of Cleansers on the Skin
This will be a single visit study that will take approximately 2 hours. Up to 50 subjects (up to 25 healthy subjects, and up to 25 subjects with AD) from BUMC dermatology clinics will be enrolled in this study and randomized to…
- Trial name
- NCT03188653
- Testing
- CeraVe® Eczema Soothing Body Wash, Cetaphil® RestoraDerm® Eczema Calming Body Wash, Dove® Sensitive Skin Body Wash
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Atopic Dermatitis
POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis
The study is a multicenter clinical trial and is designed as a proof-of-concept study to evaluate the efficacy, safety, tolerability, PK, immunogenicity, and PD of BSI-045B following SC injections.
- Trial name
- ADAMANT (NCT05932654)
- Testing
- BSI-045B
- Where
- 17 sites in United States
- Volunteers
- 22 people
- Sponsor
- Biosion, Inc.
Dermatitis, Atopic
Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis
The purpose of this study is to determine the safety and efficacy of AN2728 Topical Ointment, 2% and 0.5%, administered once a day (QD) or twice a day (BID), in the treatment of adolescents with atopic dermatitis (AD)
- Trial name
- NCT01602341
- Testing
- AN2728 Topical Ointment, 2% QD, AN2728 Topical Ointment, 0.5% QD, AN2728 Topical Ointment, 2% BID
- Where
- 17 sites in United States, Australia
- Volunteers
- 86 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Prospective Sample Collection Study Using Non-invasive Methods to Investigate Biomarkers in AD Patients
This is a prospective, multicenter, sample collection study using DermTech's non-invasive skin collection kits to evaluate genomic biomarkers and microbiome information from pediatric and adult subjects with atopic…
- Trial name
- NCT04699695
- Testing
- Biologic therapy versus no biologic therapy
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- DermTech
Atopic Dermatitis
A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADVISE (NCT04162769)
- Testing
- Etrasimod 1 mg, Etrasimod 2 mg
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 140 people
- Sponsor
- Arena Pharmaceuticals
Atopic Dermatitis (AD)
A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.
This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.
- Trial name
- NCT07230483
- Testing
- CM512
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Keymed Biosciences Co.Ltd
PGM3 Deficiency, Eosinophilic and/or Atopic Dermatitis
Natural History of Severe Allergic Inflammation and Reactions
Background: Allergic inflammation is central to allergy-related diseases and disorders, such as asthma, food allergies, and atopic dermatitis.
- Conditions
- PGM3 Deficiency, Eosinophilic and/or Atopic Dermatitis, OSMR Deficiency, Primary Localized Cutaneous Amyloidosis
- Trial name
- NCT01164241
- Where
- United States
- Volunteers
- 945 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
Safety and Efficacy of SRD441 Ointment in Patients With Atopic Dermatitis
Atopic Dermatitis is a chronic inflammatory skin disease that affect 10 to 15% of children and 2 to 10% of adults. AD is characterised by an itchy skin eruption and may cover large parts of the body.
- Trial name
- NCT00882245
- Testing
- Vehicle ointment, Ointment
- Where
- 12 sites in Bulgaria, Finland and 1 more
- Volunteers
- 93 people
- Sponsor
- Serentis Ltd.
Atopic Dermatitis
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis…
- Trial name
- NCT06808477
- Testing
- BBT001
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 237 people, healthy volunteers welcome
- Sponsor
- Bambusa Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.